#1 Clinical Trials Search in Europe

Methohexital Sodium

Methohexital Sodium, a short-acting barbiturate anesthetic, has been the subject of several clinical trials exploring its efficacy and safety in various medical procedures. These studies have primarily focused on its use in electroconvulsive therapy (ECT) for depression and as an anesthetic agent in cardioversion and general surgery. Researchers have compared Methohexital Sodium to other anesthetics like ketamine and propofol to evaluate its effectiveness, recovery time, and potential side effects.

Table of Contents

What is Methohexital Sodium?

Methohexital Sodium, also known by brand names such as Brevital, Brevimytal, or Brietal, is a medication used for general anesthesia[1][2]. It belongs to a class of drugs called barbiturates, which work by slowing down the activity of the brain and nervous system[3].

Medical Uses of Methohexital Sodium

Methohexital Sodium is primarily used for:

  • Electroconvulsive Therapy (ECT): It is commonly used as an anesthetic for patients undergoing ECT, a treatment for severe depression and some other mental health conditions[4][5].
  • Short Surgical Procedures: It can be used to induce anesthesia for brief surgical operations[1].
  • Cardioversion: This medication is sometimes used for sedation during cardioversion, a procedure to correct abnormal heart rhythms[2].

How Methohexital Sodium is Administered

Methohexital Sodium is typically administered intravenously (through a vein) by healthcare professionals in a controlled medical setting. The dosage varies depending on the specific procedure and patient characteristics:

  • For ECT: Usually given at a dose of about 0.5-1.0 mg per kilogram of body weight[4][5].
  • For cardioversion: An initial dose of 0.5 mg/kg is often used, with additional doses given if needed[2].
  • For general anesthesia in surgeries: Dosages may range from 1-1.5 mg/kg[1][3].

Comparison with Other Anesthetics

Methohexital Sodium is often compared to other anesthetic medications, particularly in research settings:

  • Propofol: Studies have compared methohexital to propofol for procedures like cardioversion. Some research suggests that methohexital might lead to faster recovery times[2].
  • Ketamine: In ECT procedures, researchers have investigated whether ketamine might offer advantages over methohexital in terms of antidepressant effects or cognitive side effects[4][5].

Potential Side Effects and Considerations

Like all medications, methohexital sodium can have side effects. Some potential effects to be aware of include:

  • Hypotension: It may cause a temporary drop in blood pressure[1].
  • Cognitive effects: When used for ECT, there may be temporary effects on memory and cognition, though these are often related to the ECT procedure itself rather than specifically to methohexital[3].
  • Respiratory effects: As with many anesthetics, it can affect breathing, which is why it’s only administered under close medical supervision[2].

It’s important to note that methohexital is always administered by trained healthcare professionals who monitor patients closely for any adverse effects.

Ongoing Research and Clinical Trials

Methohexital Sodium continues to be the subject of clinical research, particularly in the context of ECT for depression. Some areas of ongoing investigation include:

  • Comparing its effectiveness and side effect profile to other anesthetics like ketamine in ECT[4][5].
  • Evaluating its use in patients with specific health conditions, such as those taking medications that affect blood pressure[1].
  • Assessing its impact on recovery times and cognitive function in various procedures[2][3].

These ongoing studies aim to further refine the use of methohexital and improve patient outcomes in various medical procedures.

Aspect Details
Primary Uses in Trials Anesthesia for ECT in depression, cardioversion for atrial fibrillation, general anesthesia in surgery
Comparison Drugs Ketamine, Propofol
Typical Dosage 0.5-1.5 mg/kg intravenously
Main Outcome Measures Depression scores, cognitive function, recovery time, hemodynamic changes
Safety Monitoring Blood pressure, heart rate, cognitive side effects, post-anesthesia recovery
Potential Advantages Possibly shorter recovery times in some procedures (compared to other anesthetics)
Areas Needing More Research Comparative efficacy in ECT, long-term outcomes, optimal dosing strategies

FAQ

  • What is Methohexital Sodium used for in clinical trials? Methohexital Sodium is primarily used as an anesthetic agent in clinical trials for procedures such as electroconvulsive therapy (ECT) for depression, cardioversion for atrial fibrillation, and general anesthesia in surgery.
  • How does Methohexital Sodium compare to other anesthetics like ketamine in ECT trials? Clinical trials have compared Methohexital Sodium to ketamine in ECT, examining factors such as antidepressant efficacy, cognitive side effects, and recovery time. Some studies suggest ketamine may have potential advantages, but results have been mixed and more research is needed.
  • What are the typical dosages of Methohexital Sodium used in clinical trials? In the clinical trials reviewed, Methohexital Sodium dosages typically ranged from 0.5 to 1.5 mg/kg of body weight, administered intravenously. The exact dosage may vary depending on the specific procedure and patient characteristics.
  • Are there any notable side effects of Methohexital Sodium observed in clinical trials? While specific side effects were not extensively detailed in the trial summaries, researchers monitored for adverse events such as changes in blood pressure, heart rate, and cognitive function. Post-anesthesia recovery side effects like nausea, headache, and confusion were also assessed in some studies.
  • How does Methohexital Sodium affect recovery time in procedures like cardioversion? One clinical trial aimed to compare recovery time between Methohexital Sodium and propofol in cardioversion procedures. The study hypothesized that Methohexital might lead to shorter recovery times, but final results were not provided in the available information.

Ongoing Clinical Trials on Methohexital Sodium

  • Study on Esketamine and Propofol for Anesthesia in Electroconvulsive Therapy for Patients with Major Depression

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria

Glossary

  • Methohexital Sodium: A short-acting barbiturate anesthetic drug used for inducing anesthesia in various medical procedures, including electroconvulsive therapy and cardioversion.
  • Electroconvulsive Therapy (ECT): A psychiatric treatment in which seizures are electrically induced in patients to provide relief from mental disorders, most commonly used to treat severe depression.
  • Cardioversion: A medical procedure used to restore a normal heart rhythm in patients with certain types of abnormal heart rhythms (arrhythmias), such as atrial fibrillation.
  • Ketamine: An anesthetic medication that has been studied as an alternative to Methohexital in ECT procedures, with potential rapid-acting antidepressant properties.
  • Propofol: An intravenous anesthetic agent often used for inducing and maintaining general anesthesia, compared to Methohexital in some clinical trials.
  • Hamilton Rating Scale for Depression (HRSD): A multiple-item questionnaire used to provide an indication of depression and as a guide to evaluate recovery.
  • Montreal Cognitive Assessment (MoCA): A rapid screening instrument for mild cognitive dysfunction, used to assess cognitive changes in some ECT trials.
  • Ramsay Sedation Scale: A scale used to assess the depth of sedation in patients, ranging from 1 (anxious and agitated) to 6 (unresponsive).
  • Visual Analog Scale: A measurement instrument used to assess subjective characteristics or attitudes that cannot be directly measured, often used for pain assessment.
  • Hemodynamics: The study of blood flow through the cardiovascular system, including measurements of blood pressure and heart rate.

References

  1. https://clinicaltrials.gov/study/NCT02624050
  2. https://clinicaltrials.gov/study/NCT04187196
  3. https://clinicaltrials.gov/study/NCT01907217
  4. https://clinicaltrials.gov/study/NCT01367119
  5. https://clinicaltrials.eu/trial/study-on-esketamine-and-propofol-for-anesthesia-in-electroconvulsive-therapy-for-patients-with-major-depression/